{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"groups":[{"description":"Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.\n\nGlutamine: Administered orally twice daily for 21 days","id":"OG000","title":"Arm I: Glutamine"},{"description":"Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.\n\nPlacebo: Administered orally twice daily for 21 days","id":"OG001","title":"Arm II: Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 weeks from baseline while on Vincristine treatment","title":"Incidence of Vincristine-induced Peripheral Neuropathy","type":"PRIMARY","unitOfMeasure":"participants"}